All
Overview of Efalizumab Patient-reported Outcomes Trials
July 1st 2003After treatment with the new biologic agents, patient-reported outcomes measuring quality of life were evaluated, since psoriasis has been shown to have a significantly negative impact on patients' physical, psychological, and social functioning.22 Because the condition can affect the ability to perform normal work activities and often causes absence from work, psoriasis can negatively affect a person's job and income.
Overview of Efalizumab Placebo- controlled Phase III Trials
July 1st 2003Efalizumab is a humanized IgG monoclonal antibody directed against the alpha chain of LFA-1 (CD11a) expressed on the surface of T cells.11 Efalizumab blocks the interaction between LFA-1 and ICAM-1 on APCs, vascular endothelial cells, and cells in the dermis and epidermis.
Total Soy Alters Look of Male Beard
June 1st 2003San Francisco -- Topical application of a moisture-based formulation containing Total Soy can significantly reduce the appearance of male beard hair on the face and neck, according to the results of a double-blind, randomized, placebo-controlled study.
Doxorubicin, Interleukin-12 Join Against KS
June 1st 2003Boston - Combined cytotoxic and antiangiogenic therapies may have synergistic effects in treating advanced Kaposi's sarcoma in patients with AIDS, according to Richard F. Little, M.P.H., M.D., senior clinical investigator, HIV and AIDS malignancy branch, Center for Cancer Research, National Cancer Institute.
Nervous System at Root of Itch
June 1st 2003San Francisco - Uncovering and successfully treating itch may depend on how readily dermatologists accept that some cases may be related to neurological or psychological factors, John Y.M. Koo, M.D., said at the annual meeting of the American Academy of Dermatology.